FINWIRES · TerminalLIVE
FINWIRES

CR Double-Crane's Profit, Revenue Fall in Q1

By

-- China Resources Double-Crane Pharmaceutical (SHA:600062) posted net profit of 501.4 million yuan for the first quarter of 2026, down from 522.7 million yuan a year earlier, according to an April 24 Hong Kong bourse filing by parent China Resources Pharmaceutical (HKG:3320).

Revenue fell to 2.81 billion yuan from 3.08 billion yuan in the prior year period.

Related Articles